Guselkumab Adds PsA Structural Damage Inhibition to Label

Guselkumab is the only IL-23 inhibitor that has been proven to help stop further structural damage in patients with active psoriatic arthritis.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/guselkumab-adds-psoriatic-arthritis-structural-damage-2026a1000i12?src=rss

Author :

Publish date : 2026-05-29 17:39:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Guselkumab Adds PsA Structural Damage Inhibition to Label

Reassuring Data for Two High-Efficacy MS Meds in Pregnancy

Here’s Everything Wrong With the Offshore Ebola Quarantine Plan

Related Posts

Targeted Lung Cancer Drug Aces Confirmatory Trial in Frontline Setting

Cardiac Amyloidosis Diagnosis Gets a More Extensive AI Model

Enhanced MRI Tops Ultrasound in Catching Early Liver Cancer

What Did FDA Vaccine Advisors Decide This Week?

No Difference in Complications for Chiari I Surgical Approaches in Kids, Study Shows

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Targeted Lung Cancer Drug Aces Confirmatory Trial in Frontline Setting

Cardiac Amyloidosis Diagnosis Gets a More Extensive AI Model

Enhanced MRI Tops Ultrasound in Catching Early Liver Cancer

What Did FDA Vaccine Advisors Decide This Week?

No Difference in Complications for Chiari I Surgical Approaches in Kids, Study Shows

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

PCSK9 Inhibitors Linked to Better Survival in Some Cancer Patients on Immunotherapy

FDA Sets Sights on Animal Testing; AI Privacy Threat; Chewing Gum for Cancer?

Categories

Archives